CNTX
Context Therapeutics Inc.1.1000
-0.0300-2.65%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
101.07MP/E (TTM)
-Basic EPS (TTM)
-0.24Dividend Yield
0%Recent Filings
8-K
FDA Fast Track for CTIM-76
Context Therapeutics scored FDA Fast Track designation for CTIM-76, its Claudin 6 x CD3 bispecific antibody, targeting platinum-resistant ovarian cancer in patients exhausted by standard therapies. The Phase 1a trial is underway. Interim data drops in June 2026. Fast Track speeds development for this unmet need.
8-K
Pipeline update, key CTIM-76 data
Context Therapeutics updated its corporate presentation on March 23, 2026, highlighting its T cell engager pipeline for solid tumors. CTIM-76 showed a confirmed partial response with 85% tumor reduction in platinum-resistant ovarian cancer, no Grade >1 CRS, and no DLTs in 12 Phase 1a patients. Interim data due June 2026; cash lasts to mid-2027. Pipeline advances fast.
10-K
FY2025 results
Context Therapeutics posted a $36.1M net loss for FY2025 ended December 31, 2025, up 35% y/y, on $31.9M R&D (40% y/y rise) driven by CTIM-76 Phase 1 dosing in January 2025, CT-95 Phase 1 start in April 2025, and $2M CT-202 milestone. Cash burned $28.4M to $66M, funding Phase 1a escalations into mid-2027. No revenue; $66M cash supports Q4 momentum with first patients dosed. Pipeline accelerated across three TCE bispecifics. Yet funding needs loom large. Clinical delays threaten timelines.
8-K
Court voids director protections
Context Therapeutics' charter provisions locking directors to three-year terms and removal-for-cause were ruled invalid by Delaware Chancery Court on March 11, 2026, following a stockholder suit settlement. Current board terms now expire at the June 24 annual meeting. Directors removable with or without cause. Activist pressure looms.
8-K
Settles director term lawsuit
Context Therapeutics filed a stipulation on February 24, 2026, seeking court invalidation of charter provisions mandating three-year director terms and for-cause removal only. The stockholder suit dismisses with prejudice; annual meeting set for June 24, 2026, record date April 27. Company plans one-year director terms. Court approval pending.
IPO
Employees
Sector
Industry
BCAX
Bicara Therapeutics Inc.
18.15-0.21
BCTX
BriaCell Therapeutics Corp.
8.70-0.28
CBIO
Crescent Biopharma, Inc.
12.92-0.29
CLDX
Celldex Therapeutics, Inc.
26.68-0.41
CMPX
Compass Therapeutics, Inc.
5.24+0.16
CNSP
CNS Pharmaceuticals, Inc.
7.39+0.12
CTMX
CytomX Therapeutics, Inc.
4.25+0.12
IMTX
Immatics N.V.
10.09+0.11
SMMT
Summit Therapeutics Inc.
17.23-0.15
XLO
Xilio Therapeutics, Inc.
0.65+0.00